Farxiga met primary endpoint in landmark Phase III DAPA-HF trial for the treatment of patients with heart failure
AstraZeneca today announced positive results from the landmark Phase III DAPA-HF trial which showed that Farxiga (dapagliflozin) met the primary composite endpoint with a statistically-significant and clinically
Click one of our representatives below to chat on WhatsApp ,no call facility whatsaap this numbers only Chat .
Sales manager Supporter Manger
How can i help you?Sales manager Supporter MangerI am online